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Abstract
Background:  The most effective pharmacological treatments for depression inhibit the
transporters that reuptake serotonin (Selective Serotonin Reuptake Inhibitors – SSRIs) and
noradrenaline (Noradrenaline Reuptake Inhibitors – NaRIs) into the presynaptic terminal. There is
evidence to suggest that noradrenaline and serotonin enhancing drugs work through separate
mechanisms to produce their clinical antidepressant action. Although most of the current evidence
suggests there is little difference in overall efficacy between SSRIs and NaRIs, there are patients
who respond to one class of compounds and not another. This suggests that treatment response
could be predicted by genetic and/or clinical characteristics.
Firstly, this study aims to investigate the influence of a polymorphism (SLC6A4) in the 5HT
transporter in altering response to SSRI medication. Secondly, the study will investigate whether
those with more severe depression have a better response to NaRIs than SSRIs.
Methods/design: The GenPod trial is a multi-centre randomised controlled trial. GPs referred
patients aged between 18–74 years presenting with a new episode of depression, who did not have
any medical contraindications to antidepressant medication and who had no history of psychosis
or alcohol/substance abuse. Patients were interviewed to ascertain their suitability for the study.
Eligible participants (with a primary diagnosis of depression according to ICD10 criteria and a Beck
Depression Inventory (BDI) score > 14) were randomised to receive one of two antidepressant
treatments, either the SSRI Citalopram or the NaRI Reboxetine, stratified according to severity.
The final number randomised to the trial was 601. Follow-up assessments took place at 2, 6 and 12
weeks following randomisation. Primary outcome was measured at 6 weeks by the BDI. Outcomes
will be analysed on an intention-to-treat basis and will use multiple regression models to compare
treatments.
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Discussion:  The results of the trial will provide information about targeting antidepressant
treatment for individual patients; in turn this may increase prescribing efficacy, thereby speeding
recovery and reducing the cost to the NHS. It will also help to understand the different roles that
noradrenaline and serotonin might play in the biology of depression.
The trial is expected to report in the autumn of 2008.
Trial Registration: ISRCTN 31345163
Background
Depression is the most common mental disorder in com-
munity settings. Indeed, the Global Burden of Disease
study suggests that depression will be second only to car-
diovascular disease in causing disability by the year
2020[1].
Depression is an illness that is characterised by low mood
and the inability to experience pleasure. Symptoms can
impact upon the emotional, cognitive, physical and
behavioural health of the individual, although not every
patient experiences all symptoms. Behavioural and physi-
cal symptoms can include irritability, tearfulness, reduced
sleep, increased pain (with new or existing symptoms),
reduced appetite, fatigue, loss of interest in everyday life,
guilt and worthlessness. Cognitive symptoms include
poor concentration, forgetfulness, pessimism, negative
thoughts about the past and future, and slower mental
aptitude.
In the UK depression is usually treated in primary care and
in 2005 there were in excess of 29 million prescriptions
for antidepressant medication[2]. The cost of treatment
for depression in the National Health Service (£887 mil-
lion) is greater than both that for hypertension and diabe-
tes combined (£439 and £300 million respectively)[3].
However, these figures do not take account of the indirect
costs associated with depression[4], and it is also impor-
tant to consider the wider social implications of depres-
sion beyond that pertaining directly to the individual.
Social and occupational functioning is limited when an
individual is depressed, with consequently increased
dependence upon welfare and benefits. In particular, days
lost from work due to depression exceed all other disor-
ders. In 1994 an estimated 1.5 million disability-adjusted
life years were lost each year in the developed world as the
result of depression[5]. Finding an effective treatment for
depression is therefore a key consideration for the health
service.
The most effective and widely used pharmacological treat-
ments for depression inhibit the transporters that
reuptake serotonin (5-hydroxytryptamine -5HT) and
noradrenaline (NA) into the presynaptic terminal. They
demonstrate a range of affinities, from selectivity for 5HT
(SSRIs), via compounds with affinity for both NA and
5HT, to those that are selective for NA. Specific noradren-
aline reuptake inhibitors (NaRIs), such as Reboxetine,
have recently been developed. National Institute for
Health and Clinical Excellence (NICE) guidelines in the
UK recommend SSRIs as first-line pharmacological treat-
ment for moderate and severe depression. While SSRIs are
effective in many cases there are some patients who do not
respond to this medication. It has been reported however,
that some dual-acting drugs such as serotonin-noradrena-
line reuptake inhibitors (SNRIs), or tricyclic antidepres-
sants such as amitriptyline, are more efficacious when
treating patients to remission than SSRIs[6,7]. This
research suggests it is important to consider the utility of
enhancing noradrenaline activity in some patients rather
than focusing solely on increasing serotonin function.
Perhaps alternatives to SSRIs such as NaRIs may also help
in these cases.
Interactions between NA and 5HT pathways make it likely
that NA- and 5HT-potentiating drugs have some pharma-
cological actions in common, particularly after longer-
term use; however, there is now good evidence for specif-
icity of pharmacological action. Depressed patients who
have responded clinically to SSRIs relapse when 5HT but
not NA neurotransmission is interrupted. Exactly the con-
verse has been observed with patients who have
responded to NA-potentiating drugs such as
desipramine[8]. This suggests that NA and 5HT-enhanc-
ing drugs work through separate mechanisms to produce
their clinical antidepressant action, and the development
and promotion of new NaRIs is expected to occur.
Most of the current evidence suggests that there is little dif-
ference in overall efficacy between SSRIs and NaRIs[9].
Nevertheless clinical experience indicates that some
patients respond to one class of compounds and not to
the other, suggesting that treatment response could be
predicted by genetic and/or clinical characteristics. There
is, however, a dearth of reliable evidence in the literature
regarding specific predictors of (differential) response to
these two classes of medication. Previous investigations,
conducted primarily within the pharmaceutical industry,
have deficiencies such as not being available in the peer-Trials 2008, 9:29 http://www.trialsjournal.com/content/9/1/29
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reviewed literature, lack of power, unclear prior hypothe-
ses and multiple hypotheses testing.
In summary, there is currently a 30–40% chance that a
patient will not recover with a first antidepressant. If they
fail to respond to this first type of medication, the likeli-
hood that they will not respond to the second is about
50%. A method of targeting medication for an individual
based on genetic or clinical characteristics would improve
these statistics and enable GPs to prescribe more effec-
tively.
Aim
The aim of this paper is to describe the protocol for a ran-
domised controlled trial (RCT) designed to investigate
genetic and clinical predictors of treatment response to
SSRIs and NaRIs in depressive illness. There are two
hypotheses concerned with response to NaRIs and SSRIs.
1. Polymorphism in the serotonin transporter
The most interesting polymorphism in the gene that
encodes the serotonin transporter (SLC6A4) is a 44 bp-
insertion/deletion polymorphism within a repetitive unit
in the 'promoter' region. Both reporter gene analyses in
cell culture and analysis of native receptors in lymphob-
lastoid cell lines suggest that the long (insertion) form is
functionally more active than the short (deletion) form
[10,11]. Human subjects who are homozygotes for the
insertion allele (long/long) have a greater prolactin
response to fenfluramine when on SSRIs [12]. This has led
to the postulation that SSRIs would induce a greater anti-
depressant response in individuals who are homozygous
for the insertion allele – a hypothesis that has recently
been supported by two studies[13,14]. A third study from
Korea yielded a 'negative' finding[15], with more recent
studies reporting that the findings are inconsistent[16].
All these studies, however, failed to include a comparison
group to determine whether the insertion allele influ-
enced prognosis independent of any antidepressant
action.
Hypothesis 1
Those who are homozygous for the insertion allele poly-
morphism in the promoter region of the 5HT transporter
(SLC6A4) who are allocated SSRIs will have an improved
response compared to those on NaRIs. This also implies
that those who are not homozygous will have reduced
response on SSRIs compared to those on NaRIs.
2. Severity of illness
There has been anecdotal clinical evidence that those with
more severe depression are more likely to respond to anti-
depressants with NaRI properties. More formally, two
studies have suggested that NaRI is more effective in the
more severe depressions[17,18]. It should be noted that
severity of depression overlaps with the presence of
'endogenous' or 'biological' symptoms, which in the past
were used as clinical indications for antidepressant use.
For simplicity, the hypothesis has been formulated here in
terms of severity of illness.
Hypothesis 2
Those who have more severe depressive disorders who are
allocated NaRIs and those who have less severe disorders
allocated SSRIs will have a better response compared to
the other two groups of patients.
Methods/design
Recruitment of participants and baseline assessment
The study is a multi-centred randomised controlled trial
(shown in figure 1) in which patients with depression,
recruited in primary care, were randomly allocated to
either an NaRI (Reboxetine) or an SSRI (Citalopram). The
study includes those aged between 18–74 with the rela-
tively more severe episodes of depression in whom the GP
and patient had already agreed that antidepressants
should be prescribed. The study is being conducted in
three centres within the UK; Bristol, Birmingham and
Newcastle. In accordance with the Declaration of Helsinki
full ethical approval has been obtained from the South
West Ethical Board as well as research governance
approval from the Bristol, Manchester and Newcastle
PCTs.
The study excluded potential participants who have taken
antidepressant medication within two weeks leading up
to the baseline assessment and those who could not com-
plete self-administered scales. Moreover, GPs excluded
anyone who had medical contraindications or in whom
participation in the trial was not deemed appropriate, as
well as those who had psychosis, bipolar disorder or
major substance or alcohol abuse.
Having secured their written agreement to be contacted by
the GenPod research study team, GPs referred suitable
patients to the research team by fax, and researchers then
contacted the patients directly, inviting them to partici-
pate in the study. The researchers visited patients either at
home or at the patients' own surgery to assess eligibility
and to obtain informed consent for participation within
the trial. At the baseline assessment only those patients
with a diagnosis of ICD-10 depressive episode F32 from
the Clinical Interview Schedule-Revised (CIS-R)[19] and a
Beck Depression Inventory (BDI)[20] score of ≥ 15, were
eligible to continue in the study. The final number ran-
domised in the trial was 601 subjects.
The CIS-R is a fully structured interview that measures
neurotic psychopathology and was designed to detect
ICD-10 neurotic disorders. The survey asks questionsTrials 2008, 9:29 http://www.trialsjournal.com/content/9/1/29
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about the presence of 14 symptom groups in the week
prior to interview, with questions to identify the onset and
duration of each episode. The BDI is a 21-item self report
rating inventory constructed to measure attitudes, severity
and symptoms of depression (consistent with DSM-IV cri-
teria), as well as the efficacy of antidepressants. It is not
intended as an instrument for specifying clinical diagno-
sis.
Further measures were collected from eligible patients at
baseline, including the SF-12 health questionnaire[21],
the Hospital Anxiety and Depression Scale (HADS)[22], a
measure of physical symptoms using a modified version
of the Toronto Side Effects Scale[23], and the Big Five
Inventory personality scale (BFI-44)[24].
Randomisation procedure
Once patients have met the eligibility criteria for both of
these measures they were then randomised to receive one
of the two antidepressant medications described above.
Randomisation was conducted by means of a computer-
generated code, administered centrally and communi-
cated by telephone and thereby concealed in advance
from the research assistant. The assigned medication was
given to the participant by the research assistant – effec-
tively prescribed by the lead GenPod clinician in the
recruiting centre with the agreement of the patient's GP.
Overall clinical responsibility for the patient remained
with the GP, who was informed of the allocation.
To ensure reasonable balance between the two treatment
groups over time in respect of severity, which is the most
important prognostic indicator[19], allocation was strati-
fied by severity of depressive episode (CIS-R total score ≥
28 is classed as severe, below this is classed as moderate),
and also stratified by centre using variable block sizes to
maximise concealment.
DNA Sampling
At the baseline assessment, blood samples were also taken
from the eligible patients in order to investigate the poten-
tial links with the SLC6A4 gene. DNA will be extracted
and banked by the Cardiff MRC Co-operative Group in
NeuroPsychiatric Genetics, a group with extensive experi-
ence of banking DNA under MRC guidelines. Stock DNA
will be stored at -20 in a linked anonymised format, with
codes held by the Principal Investigator (GL). 27 ml of
blood will be taken at the initial assessment and is
expected to yield an average of 800 μg.
Interventions
Both interventions are medicinal. Trial participants were
randomised to receive either 4 mg of reboxetine twice
daily or 20 mg of citalopram daily. Both medications are
believed to be equally effective. The patient was given 6
weeks medication at baseline and the remainder at the 6-
week follow-up appointment.
(i) Citalopram
Citalopram (brand name Cipramil) is a selective serotonin
reuptake inhibitor (SSRI) that is licensed to treat depres-
sion and also to treat panic disorder. It works by inhibit-
ing the reuptake of the neurotransmitter serotonin from
its site of action at the synaptic cleft. By doing so citalo-
pram may prolong the actions of serotonin and this is
likely to be the mechanism that underlies its therapeutic
action.
SSRIs are often preferred to the tricyclic antidepressants
(TCAs) because the side effects of SSRIs are generally bet-
A flowchart of the GenPod trial design Figure 1
A flowchart of the GenPod trial design.
Initial patient consultation with GP 
Patient is given Patient Information Sheet and gives consent for GP to 
contact GenPod 
GP refers patient to GenPod via Fax 
GenPod researcher contacts patient 
Baseline assessment arranged 
Baseline assessment 
Eligibility is determined by responses to CIS-R and 
BDI assessments
Patient eligible 
Researcher telephones randomisation service to 
receive allocation of treatment
Patient randomised to 
Citalopram 
Patient randomised to 
Reboxetine 
2-week telephone assessment 
Side effects profile, medication compliance and 
suicidal ideation collected 
6-week assessment 
Primary clinical outcome collected (BDI score) 
Secondary outcomes collected (SF12, HADS, BFI-44, 
Side effects profile, medication compliance) 
12-week assessment 
Secondary outcomes collected (BDI, SF12, HADS, 
BFI-44, Side effects profile, medication compliance)Trials 2008, 9:29 http://www.trialsjournal.com/content/9/1/29
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ter tolerated. SSRIs are also safer in overdose for patients
who are highly suicidal.
(ii) Reboxetine
Reboxetine (brand name Edronax) is a noradrenaline
reuptake inhibitor (NaRI) licensed as an antidepressant.
Low noradrenaline activity in the brain is believed to be
one possible cause of depression. Reboxetine works by
inhibiting the re-uptake of noradrenaline, and therefore
restoring the levels of noradrenaline in the body. It is also
believed to help relieve some of the associated symptoms
of depression such as fatigue and anxiety.
Reboxetine is the first NaRI to be marketed and therefore
relatively little is known about its tolerance in comparison
with other more established types of antidepressants. The
use of reboxetine in the current study will provide data on
the side effect profile of this medication within this pri-
mary care population.
Follow-up
Clinical outcome data were recorded 6 and 12 weeks after
randomisation. However, since side effects are most com-
monly experienced in the first two weeks of treatment, an
additional telephone follow-up was administered after 2
weeks to assess side effects, suicidal ideation and adher-
ence with medication. The latter will be used to identify
individuals to be included in the explanatory secondary
analyses described below.
The questionnaires assessing outcome are all self-admin-
istered. The research associate (RA) made an appointment
at baseline to meet with the patient again at 6 weeks, at
which point the RA also gave the patient the second 6
week batch of medication. Those who did not attend this
appointment were telephoned to offer a further appoint-
ment or to fill out the questionnaire by post if meeting
was proving to be problematic. At the 6-week assessment
an arrangement was made to meet again for the final time
at 12 weeks.
It is expected that maximum treatment response to antide-
pressants would have occurred at 6 weeks (although the
patients may continue to improve after that time). The 12-
week follow-up is carried out as an indicator of a more
persistent response to treatment. After exit from the trial,
the general practitioner continues prescribing the medica-
tion for as long as clinically indicated.
Outcome measures
Primary Outcome
The total BDI score at 6 weeks in a continuous form. This
was chosen over a binary variable as use of the total BDI
score should increase statistical power.
Secondary Outcomes
- Total BDI score at 12 weeks;
- proportion 'in remission' (defined as a total BDI score <
10) at 6 and 12 weeks;
- SF-12 at 6 and 12 weeks;
- HADS at 6 and 12 weeks;
- BFI-44 at 6 and 12 weeks;
- Side effects profile at 2, 6 and 12 weeks;
- Medication compliance at 2, 6 and 12 weeks.
Statistical analysis
The analysis and reporting of this trial will be in full
accordance with the CONSORT guidelines[25]. The par-
ticipants in the trial will be compared with those eligible
but not randomised using appropriate descriptive statis-
tics and tests for means and proportions. Baseline compa-
rability of the two randomisation groups will be
ascertained using descriptive statistics. Moreover, the
anticipated similarity of the two groups overall at follow-
up will be verified using regression models to provide
95% confidence intervals of differences between the SSRI
and NaRI groups in mean 6-week and 12-week BDI
adjusting for baseline BDI and stratification. If necessary,
similar analyses will be conducted for other secondary
outcomes.
The primary comparative analyses for this trial are two
pre-specified subgroup analyses for the primary outcome
of BDI score at 6 weeks, with analysis performed on an
intention-to-treat basis. Both of these will be investigated
by introducing the interaction between treatment and the
relevant binary predictor variable (genotype or severity)
into a multiple regression model for the primary outcome
(log transformed if appropriate), adjusting for baseline
BDI score and stratification. The impact of missing values
will be investigated in sensitivity analyses involving vari-
ous assumptions and the use of substituted values.
Further secondary analyses will investigate alternative
forms of the predictor variables. For instance, a separate
category will be considered for those heterozygous for the
insertion allele, as will continuous variables for severity
(CIS-R). Other secondary analyses will also involve
explanatory analyses such as models accounting for the
degree of adherence with treatment. In particular, to com-
plement the primary intention-to-treat comparison of the
two groups, an 'explanatory' analysis will be conducted
including only the 90% of participants who from early
experience with the trial are continuing with their allo-Trials 2008, 9:29 http://www.trialsjournal.com/content/9/1/29
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cated medication at least three weeks after randomisation.
As necessary, the above analyses will be repeated for all
the secondary outcomes, using linear, logistic or repeated
measures regression as necessary.
Justification of the sample size
The sample size calculation for the GenPod trial
employed a binary version of the primary outcome (BDI
at 6 weeks) to facilitate both its formulation and interpre-
tation. Specifically, the outcome was taken to be that of
'remission' (attaining a score of < 10 on BDI at 6 weeks).
The transporter allele was also represented by a binary var-
iable even though, in the absence of dominance or heter-
osis, heterozygotes would be expected to be intermediate
in effect between the homozygotes. Both these
approaches would be anticipated to be conservative in the
sense of leading if anything to an underestimate of statis-
tical power. In addition, the formulations all used a (2-
sided) 5% significance level since although the two prin-
cipal (subgroup) analyses involve the same outcome they
are few in number (similar to the number of primary out-
comes often involved in pragmatic trials) and reflect dis-
tinct hypotheses and types of predictor variables. Lastly, it
was specified that remission would occur in 65% of par-
ticipants (on average) in 6 weeks, regardless of the antide-
pressant used.
Given that the primary hypotheses related to interactions
between 'exposures' on an outcome variable, the sample
size was determined using a computer program for such
situations available from the National Cancer Institute
(NCI) based on the methods of Lubin and col-
leagues[26,27]. As would be expected in the context of
interaction effects for binary variables, the sample size is
large and very sensitive to the assumptions that are
made[28,29]. Moreover, as is common for large-scale ran-
domised trials in a community-based setting, recruitment
to the GenPod trial was expected to be challenging, and in
the event the accrual of patients into the trial in Bristol was
even slower than anticipated. Hence as part of a request
for extended funding (in addition to widening recruit-
ment to a further two centres – Birmingham and Newcas-
tle), a revised power calculation was presented. The
description given here will therefore cover the original
sample size calculation – in particular, the key specifica-
tions including (detectable) target effect sizes – and the
implications of what currently is the likely final achieved
sample size.
In relation to the transporter hypothesis, studies in the UK
have observed 25% homozygous for the insertion allele
and 50% heterozygous[30,30,31]. This accords with
results from an Italian sample[13] and the frequency was
therefore assumed to be 25%. In the original proposal it
was stated that a substantial differential effect would be
observed if the proportions in remission at 6 weeks were
as follows: 80% among homozygotes for the insertion
allele (l/l) on SSRIs, 65% in the NaRI group and 60%
recovery for the remainder (s/l and s/s) on SSRIs and 65%
recovery on NaRIs With 90% power it was calculated that
this would require 754 subjects in total, increased to 887
to allow for 15% attrition at 6-weeks. This corresponds to
an interaction odds ratio (θ) of 0.375. For the severity
hypothesis, from previous data obtained from primary
care by the research team, it was assumed in the original
protocol that 44% would be in the more severely
depressed group (≥ 28 on the CIS-R). With a target differ-
ential effect of 75% remission in the low severity/SSRI and
high severity/NaRI groups compared with 55% remission
in the other two groups, 282 participants would be
needed for 90% power. The target sample size of 887 was
therefore driven principally (and again conservatively) by
the transporter hypothesis.
The extension request contained a range of revised likely
sample sizes predicted to be available for analysis in both
the intention-to-treat (ITT) and explanatory analyses; the
resultant target for the ITT analyses was 676 followed up
at 6 weeks, with lower power than originally (80% rather
than 90%) but no reduction in sensitivity to the (trans-
porter) interaction. The details given here have been fur-
ther informed by the continuing (challenging) experience
of recruitment to the trial, albeit with continuing high lev-
els of follow-up – well over 90% at 6 weeks. Given the
number randomised when the extension request was
made, a final target of 570 for (primary) analysis was con-
sidered to be achievable, assuming the high follow-up rate
continued.
We have also been able to estimate the actual remission
rates in the trial and these were substantially less than the
65% expected. We have observed a 25% proportion with
remission; therefore, the power calculations below have
used this result.
The primary analysis proposes to use BDI score as a con-
tinuous outcome. One method of estimating the reduc-
tion in power is to compare the power for a main effect
with the original sample size and the final target sample
size of 570. Using Nquery, the power for a main effect was
reduced by 9.1%. This calculation, of course, gives an
approximate estimate of the reduction in power, if we
assume that in broad terms, the reduction in power for the
main effect will be similar to that for an interaction term.
We also used the Lubin method (as above) and estimated
that an interaction odds ratio (θ) of 0.33 could be
detected with 80% power at the 5% level, based upon sim-
ilar assumptions to those described above. This compares
with the equivalent figures in the original power calcula-
tions of 90% power to detect a θ of 0.375, in turn translat-Trials 2008, 9:29 http://www.trialsjournal.com/content/9/1/29
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ing to remission rates of 25% for NaRI and 36.8%/19.1%
for homozygous/remainder in the SSRI group.
The figures presented here provide a realistic indication of
the sensitivity of the GenPod trial to the primary interac-
tions of interest. In addition, the detectable interactions
retain the conservative aspects of the original specifica-
tion: firstly, we have used a binary outcome rather than
the continuous version that will be employed in the pri-
mary analysis; second, we focus on the transporter
hypothesis for which power will be smaller; simplification
of this exposure to binary homozygotes versus the
remainder, whereas, the heterozygotes having an interme-
diate value is more in keeping with the likely biology. We
have concluded that, given the uncertainties about the
assumptions underpinning the power calculations, the
shortfall in recruitment will have a relatively small impact
on the ability of the trial to answer the primary research
questions posed.
Discussion
This randomised trial will address two important clinical
questions. First, it will aid clinical decision-making and
provide a rationale for targeting antidepressant treatment.
It will allow GPs and psychiatrists to prescribe first line
treatment with a higher prospect of effectiveness, thereby
speeding recovery, and reducing the cost to the NHS.
Pharmacogenetics is still widely viewed as a futuristic sci-
ence. However, it is already possible in a research labora-
tory to conduct genotyping in less than 24 hours. Fully
automated 'lab on a chip' technology will speed this proc-
ess, reduce expense and improve availability. Predictive
allele profiling could soon be a simple blood test[32,33].
The second advance is in improving our understanding of
the biology of depression. At present, the different role of
NA and 5HT in the psychopathology of depression is
uncertain. Indeed, the study could contribute to the devel-
opment of a clinically useful and biologically valid system
for sub-typing depression.
To avoid statistical problems with multiple testing and to
focus on the prior hypotheses posited, genotyping in the
GenPod trial itself is being restricted to a single polymor-
phism. There are, however, many polymorphisms within
other genes that may plausibly be involved in treatment
response. DNA is therefore being extracted and banked to
yield a major pharmacogenetics resource that will extend
beyond the lifespan of this trial. In the future, this will
facilitate provision of truly independent support or refuta-
tion of hypotheses generated by other researchers, or even
enable the development of genome-wide SNP profiles
predicting response[32].
Current Study Status
The GenPod trial started recruiting participants in Septem-
ber 2005, and is due to complete data collection in March
2008.
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